专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009117095A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：用于治疗相关疾病的前列腺素（PGI2）受体的调节剂
公开(公告)号：WO2009117095A1
公开(公告)日：2009-09-24
申请号：PCT/US2009/001688
申请日：2009-03-17
申请人： ARENA PHARMACEUTICALS, INC. , TRAN, Thuy-Anh , CHEN, Weichao , KRAMER, Bryan, A. , SADEQUE, Abu, J.M. , SHYFRYNA, Hanna, L. , SHIN, Young-Jun , VALLAR, Pureza , ZOU, Ning
发明人： TRAN, Thuy-Anh , CHEN, Weichao , KRAMER, Bryan, A. , SADEQUE, Abu, J.M. , SHYFRYNA, Hanna, L. , SHIN, Young-Jun , VALLAR, Pureza , ZOU, Ning
IPC分类号： A61K31/17 , A61K31/27 , C07C271/08 , C07C275/18 , A61P43/00
CPC分类号： A61K31/195 , A61K31/27 , A61K31/325 , A61K31/381 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4965 , C07B2200/07 , C07B2200/13 , C07C271/12 , C07C271/28 , C07C275/24 , C07C275/28 , C07C275/30 , C07C275/34 , C07C309/15 , C07C2601/14 , C07D213/75 , C07D241/20 , C07D277/48 , C07D333/36
摘要： The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).
摘要翻译：本发明涉及式（XIIIa）的酰胺衍生物及其调节PGI 2受体活性的药物组合物。本发明的化合物及其药物组合物涉及可用于治疗肺动脉高压（PAH）的方法; 特发性PAH; 家族性PAH; PAH与胶原血管疾病，先天性心脏病，门静脉高压，HIV感染，摄入药物或毒素，遗传性出血性毛细血管扩张症，脾切除术，肺静脉闭塞性疾病（PVOD）或肺毛细血管血管病变（PCH）有关）。 PAH具有明显的静脉或毛细血管介入; 血小板聚集; 冠状动脉疾病; 心肌梗死; 短暂性脑缺血发作; 心绞痛; 行程; 缺血再灌注损伤; 再狭窄; 房颤; 在血管成形术或冠状动脉旁路手术个体或患有心房颤动的个体中血凝块形成; 动脉粥样硬化; 动脉粥样硬化; 哮喘或其症状; 糖尿病性相关疾病如糖尿病性周围神经病变，糖尿病性肾病或糖尿病性视网膜病变; 青光眼或其他眼睛异常眼内疾病; 高血压; 炎; 银屑病; 牛皮癣关节炎类风湿关节炎; 克罗恩病; 移植排斥反应多发性硬化症系统性红斑狼疮（SLE）; 溃疡性结肠炎缺血再灌注损伤; 再狭窄; 动脉粥样硬化; 粉刺; 1型糖尿病; 2型糖尿病; 败血症; 和慢性阻塞性肺疾病（COPD）。

2. 发明申请

WO2007136703A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为用于治疗相关疾病的5-HT2A丝氨酸蛋白受体的调节剂的主要氨基酸及其衍生物
公开(公告)号：WO2007136703A1
公开(公告)日：2007-11-29
申请号：PCT/US2007/011834
申请日：2007-05-17
申请人： ARENA PHARMACEUTICALS, INC. , TEEGARDEN, Bradley , CHAPMAN, Dennis , CHOI, Juyi , FEICHTINGER, Konrad , HAN, Sangdon , JAYAKUMAR, Honnappa , TRAN, Thuy-Anh , XU, Jingdong , ZOU, Ning
发明人： TEEGARDEN, Bradley , CHAPMAN, Dennis , CHOI, Juyi , FEICHTINGER, Konrad , HAN, Sangdon , JAYAKUMAR, Honnappa , TRAN, Thuy-Anh , XU, Jingdong , ZOU, Ning
IPC分类号： C07D231/12 , C07D231/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , A61K31/415 , A61K31/4155 , A61P7/00
CPC分类号： A61K31/415 , C07D231/12 , C07D231/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.
摘要翻译：本发明涉及调节5-HT 2A 2 5-羟色胺受体活性的某些式（Ia）化合物及其药物组合物。化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法，精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，以及睡眠障碍，睡眠障碍，糖尿病性精神病，精神病性精神病，精神病性精神病，精神病性精神病，相关疾病，进行性多灶性脑白质病等。本发明还涉及与分开或一起施用的其它药剂组合治疗5-HT 2A 5-羟色胺受体相关疾病的方法。

3. 发明申请

WO2010068242A1 PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为用于治疗相关疾病的前列腺素（PGI2）受体的调节剂的吡咯烷基取代的碳酸衍生物
公开(公告)号：WO2010068242A1
公开(公告)日：2010-06-17
申请号：PCT/US2009/006251
申请日：2009-11-24
申请人： ARENA PHARMACEUTICALS, INC. , TRAN, Thuy-Anh , IBARRA, Jason, B. , SHIN, Young-Jun , ULLMAN, Brett , ZOU, Ning , ZENG, Xi
发明人： TRAN, Thuy-Anh , IBARRA, Jason, B. , SHIN, Young-Jun , ULLMAN, Brett , ZOU, Ning , ZENG, Xi
IPC分类号： C07D231/12 , C07D231/18 , C07D231/54 , C07D231/56 , C07D401/04 , C07D405/04 , C07D409/04 , A61K31/415 , A61K31/4155 , A61K31/416 , A61P9/00 , A61P11/00
CPC分类号： C07D409/04 , A61P9/00 , A61P11/00 , C07D231/12 , C07D231/18 , C07D231/54 , C07D231/56 , C07D401/04 , C07D405/04
摘要： Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).
摘要翻译：式Ia的吡唑衍生物及其药物组合物，其调节PGI 2受体的活性。本发明的化合物及其药物组合物涉及可用于治疗肺动脉高压（PAH）和相关疾病的方法; 血小板聚集; 冠状动脉疾病; 心肌梗死; 短暂性脑缺血发作; 心绞痛; 行程; 缺血再灌注损伤; 再狭窄; 房颤; 在血管成形术或冠状动脉旁路手术个体或患有心房颤动的个体中血凝块形成; 动脉粥样硬化; 动脉粥样硬化; 哮喘或其症状; 糖尿病性相关疾病如糖尿病性周围神经病变，糖尿病性肾病或糖尿病性视网膜病变; 青光眼或其他眼睛异常眼内疾病; 高血压; 炎; 银屑病; 牛皮癣关节炎类风湿关节炎; 克罗恩病; 移植排斥反应多发性硬化症系统性红斑狼疮（SLE）; 溃疡性结肠炎缺血再灌注损伤; 再狭窄; 动脉粥样硬化; 粉刺; 1型糖尿病; 2型糖尿病; 败血症; 和慢性阻塞性肺疾病（COPD）。

4. 发明申请

WO2016058161A1 METHOD, APPARATUS AND SYSTEM FOR USING USER EQUIPMENT AS SMALL EVOLVED NODEB FOR SMALL CELL 审中-公开
标题翻译：方法，使用用户设备作为小型小型小型NODEB的装置和系统
公开(公告)号：WO2016058161A1
公开(公告)日：2016-04-21
申请号：PCT/CN2014/088741
申请日：2014-10-16
申请人： INTEL CORPORATION , ZHU, Yuan , ZHANG, Yuan , LIU, Yinhui , ZOU, Ning
发明人： ZHU, Yuan , ZHANG, Yuan , LIU, Yinhui , ZOU, Ning
IPC分类号： H04W36/36
CPC分类号： H04L69/08 , H04L5/001 , H04L12/1435 , H04L69/167 , H04W4/24 , H04W8/205 , H04W76/27 , H04W84/20 , H04W84/22 , H04W88/04
摘要： A device, method and system of using a first user equipment (UE) as a small evolved NodeB (eNB) for a small cell may comprise receiving a first long term evolution (LTE) packet from a second UE over the small cell; converting the first LTE packet into a first transmission control protocol/Internet protocol (TCP/IP) packet, wherein the converting includes retrieving payload data from the first LTE packet and encapsulating the payload data into the first TCP/IP packet by adding a TCP/IP header to the payload data， and wherein the TCP/IP header includes an IP address of an Evolved Packet Core (EPC) network associated to Internet based on a TCP/IP tunneling protocol; and transmitting the first TCP/IP packet to an Internet destination Via the EPC connected with the first UE through an Internet server over a local area network (LAN).
摘要翻译：使用第一用户设备（UE）作为小小区的小演进节点B（eNB）的设备，方法和系统可以包括：在小小区上从第二UE接收第一长期演进（LTE）分组; 将所述第一LTE分组转换为第一传输控制协议/因特网协议（TCP / IP）分组，其中所述转换包括从所述第一LTE分组检索有效载荷数据，并通过添加TCP / IP分组将所述有效载荷数据封装到所述第一TCP / IP分组中， IP头到所述有效载荷数据，并且其中所述TCP / IP报头包括基于TCP / IP隧道协议的与因特网相关联的演进分组核心（EPC）网络的IP地址; 以及经由局域网（LAN）通过因特网服务器通过与第一UE连接的EPC将第一TCP / IP分组发送到因特网目的地。

5. 发明申请

WO2010077275A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：用于治疗相关疾病的前列腺素（PGI2）受体的调节剂
公开(公告)号：WO2010077275A1
公开(公告)日：2010-07-08
申请号：PCT/US2009/006408
申请日：2009-12-07
申请人： ARENA PHARMACEUTICALS, INC. , TRAN, Thuy-Anh , HAYASHI, Rena , IBARRA, Jason B. , ULLMAN, Brett , ZOU, Ning
发明人： TRAN, Thuy-Anh , HAYASHI, Rena , IBARRA, Jason B. , ULLMAN, Brett , ZOU, Ning
IPC分类号： C07D237/14 , C07D401/04 , C07D403/04 , C07D409/04 , C07D253/07 , A61K31/50 , A61K31/501 , A61K31/53 , A61P11/08
CPC分类号： C07D237/14 , C07D253/07 , C07D401/04 , C07D403/04 , C07D409/04
摘要： Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).
摘要翻译：式Ia的环己烷衍生物及其药物组合物，其调节PGI 2受体的活性。本发明的化合物及其药物组合物涉及可用于治疗肺动脉高压（PAH）和相关疾病的方法; 血小板聚集; 冠状动脉疾病; 心肌梗死; 短暂性脑缺血发作; 心绞痛; 行程; 缺血再灌注损伤; 再狭窄; 房颤; 在血管成形术或冠状动脉旁路手术个体或患有心房颤动的个体中血凝块形成; 动脉粥样硬化; 动脉粥样硬化; 哮喘或其症状; 糖尿病性相关疾病如糖尿病性周围神经病变，糖尿病性肾病或糖尿病性视网膜病变; 青光眼或其他眼睛异常眼内疾病; 高血压; 炎; 银屑病; 牛皮癣关节炎类风湿关节炎; 克罗恩病; 移植排斥反应多发性硬化症系统性红斑狼疮（SLE）; 溃疡性结肠炎缺血再灌注损伤; 再狭窄; 动脉粥样硬化; 粉刺; 1型糖尿病; 2型糖尿病; 败血症; 和慢性阻塞性肺疾病（COPD）。

6. 发明申请

WO2004087669A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF 审中-公开
标题翻译：新颖的喹啉，四氢喹诺酮和哌嗪衍生物及其使用相关的治疗方法
公开(公告)号：WO2004087669A1
公开(公告)日：2004-10-14
申请号：PCT/JP2004/004624
申请日：2004-03-31
申请人： TAISHO PHARMACEUTICAL CO. LTD. , ARENA PHARMACEUTICALS INC. , SEKIGUCHI, Yoshinori, , KANUMA, Kosuke, , OMODERA, Katsunori, , BUSUJIMA, Tsuyoshi, , TRAN, Thuy-Anh, , HAN, Sangdon, , CASPER, Martin, , KRAMER, Bryan, A., , SEMPLE, Graeme, , ZOU, Ning,
发明人： SEKIGUCHI, Yoshinori, , KANUMA, Kosuke, , OMODERA, Katsunori, , BUSUJIMA, Tsuyoshi, , TRAN, Thuy-Anh, , HAN, Sangdon, , CASPER, Martin, , KRAMER, Bryan, A., , SEMPLE, Graeme, , ZOU, Ning,
IPC分类号： C07D215/42
CPC分类号： C07D239/48 , C07D215/42 , C07D239/94 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.
摘要翻译：本发明涉及作为MCH受体拮抗剂的式（I）的新化合物。这些组合物可用于药物组合物，其用途包括预防或治疗改善记忆功能，睡眠和觉醒，焦虑，抑郁，情绪障碍，癫痫发作，肥胖症，糖尿病，食欲和进食障碍，心血管疾病，高血压，血脂异常，心肌梗塞，包括贪食症，厌食症，包括躁狂抑郁症，精神分裂症，del妄，痴呆，压力，认知障碍，注意力缺陷障碍，药物滥用障碍和包括帕金森氏病，癫痫和成瘾在内的运动障碍的暴饮暴食症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式